Maybe you can talk to me a little about when drugs are assessed for their effectiveness. We have generic ones and then we have non-generic ones, of course. When that assessment takes place, if provinces had to take the money that we allocate to them to pay for those pharmaceuticals, is it possible that those provinces could choose to pay for, let's say, the less effective one if it happens to be cheaper and still approved rather than paying for the more effective one, which happens to be more expensive? Could we find ourselves in a situation where people are simply prescribed a drug that isn't really effective but that's just the way it is because provinces are looking to save money?
On April 13th, 2016. See this statement in context.